Aims: To evaluate the efficacy and safety of antidiabetes treatment in adjunct to insulin in type 1 diabetes.
Methods: A systematic search of MEDLINE, Embase and Cochrane Central Register of Controlled Trials was made from the beginning date to June 2018.
Results: A total of 48 studies were included in the meta-analysis. Compared with placebo, treatment with metformin, treatment with a-glucosidase inhibitor (AGI), treatment with GLP-1 receptor agonist, treatment with SGLT2 inhibitor, treatment with pramlintide all showed significant decrease in HbA1c from baseline (Table 1). Compared with placebo, treatment with metformin, treatment with GLP-1 receptor agonist, treatment with SGLT2 inhibitor, treatment with pramlintide all resulted in significant decrease in insulin dosage from baseline (Table 1).
Conclusion: Compared with placebo, in type 1 diabetes patients, in adjunctive to insulin treatment, treatment with metformin, treatment with GLP-1 receptor agonist, treatment with SGLT2 inhibitor, treatment with pramlintide all resulted in significant decrease in HbA1c and insulin dosage from baseline.
X. Cai: None. W. Yang: None. S. Zhang: None. L. Ji: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck KGaA, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk A/S, Roche Pharma, Sanofi, Takeda Pharmaceutical Company Limited. Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Roche Pharma, Sanofi.
